PERCOCET- oxycodone hydrochloride and acetaminophen tablet Endo USA, Inc.

PERCOCET[®] (Oxycodone and Acetaminophen Tablets, USP) CII Rx only

Revised: June 2024

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF PERCOCET

Addiction, Abuse, and Misuse

Because the use of PERCOCET exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see WARNINGS].

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression may occur with use of PERCOCET, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of PERCOCET are essential *[see WARNINGS]*.

Accidental Ingestion

Accidental ingestion of even one dose of PERCOCET, especially by children, can result in a fatal overdose of Oxycodone [see WARNINGS].

<u>Risks From Concomitant Use With Benzodiazepines Or Other CNS</u> <u>Depressants</u>

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of PERCOCET and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate [see WARNINGS, PRECAUTIONS; Drug Interactions].

Neonatal Opioid Withdrawal Syndrome (NOWS)

If opioid use is required for an extended period of time in a pregnant woman, advise the patient of the risk of NOWS, which may be lifethreatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery [see WARNINGS].

Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)

Healthcare providers are strongly encouraged to complete a REMScompliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription [see WARNINGS].

Cytochrome P450 3A4 Interaction

The concomitant use of PERCOCET with all cytochrome P450 3A4 inhibitors may result in an increase in oxycodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in oxycodone plasma concentration. Monitor patients receiving PERCOCET and any CYP3A4 inhibitor or inducer [see CLINICAL PHARMACOLOGY, WARNINGS, PRECAUTIONS; Drug Interactions].

Hepatotoxicity

Acetaminophen has been associated with cases of acute liver failure, at

times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.

DESCRIPTION


Oxycodone Hydrochloride and Acetaminophen is available in tablets for oral administration.

Each tablet for oral administration, contains oxycodone hydrochloride and acetaminophen in the following strengths:


Oxycodone Hydrochloride, USP 2.5 ma* (*2.5 mg oxycodone hydrochloride is equivalent to 2.2409 mg of oxycodone.) Acetaminophen, USP 325 mg 5 mg* Oxycodone Hydrochloride, USP (*5 mg oxycodone hydrochloride is equivalent to 4.4815 mg of oxycodone.) Acetaminophen, USP 325 mg Oxvcodone Hvdrochloride, USP 7.5 ma* (*7.5 mg oxycodone hydrochloride is equivalent to 6.7228 mg of oxycodone.) Acetaminophen, USP 325 mg Oxycodone Hydrochloride, USP 10 ma* (*10 mg oxycodone hydrochloride is equivalent to 8.9637 mg of oxycodone.) Acetaminophen, USP 325 mg

All strengths of PERCOCET also contain the following inactive ingredients: Colloidal silicon dioxide, croscarmellose sodium, microcrystalline cellulose, povidone, pregelatinized cornstarch, and stearic acid. May also contain crospovidone. In addition, the 2.5 mg/325 mg strength contains FD&C Red No. 40 Aluminum Lake and the 5 mg/325 mg strength contains FD&C Blue No. 1 Aluminum Lake. The 7.5 mg/325 mg strength contains FD&C Yellow No. 6 Aluminum Lake. The 10 mg/325 mg strength contains D&C Yellow No. 10 Aluminum Lake. The 7.5 mg/325 mg strength may also contain corn starch.

Oxycodone Hydrochloride and Acetaminophen Tablets contain oxycodone, 14hydroxydihydrocodeinone, a semisynthetic opioid analgesic which occurs as a white to off-white fine crystalline powder. The molecular formula for oxycodone hydrochloride is $C_{18}H_{21}NO_4 \cdot HCl$ and the molecular weight is 351.82. It is derived from the opium alkaloid, thebaine, and may be represented by the following structural formula:



Oxycodone Hydrochloride and Acetaminophen Tablets contain acetaminophen, 4'hydroxyacetanilide, is a non-opiate, non-salicylate analgesic and antipyretic which occurs as a white, odorless, crystalline powder. The molecular formula for acetaminophen is $C_8H_9NO_2$ and the molecular weight is 151.16. It may be represented by the following structural formula:



C₈H₉NO₂ MW 151.16

CLINICAL PHARMACOLOGY

Mechanism of Action

Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone.

Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.

The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have been identified throughout the brain and spinal cord and are thought to play a role in the analgesic effects of this drug.

The precise mechanism of the analgesic properties of acetaminophen is not established but is thought to involve central actions.

Pharmacodynamics

Effects on the Central Nervous System

Oxycodone produces respiratory depression by direct action on brain stem respiratory centers. The respiratory depression involves a reduction in the responsiveness of the brain stem respiratory centers to both increases in carbon dioxide tension and electrical stimulation.

Oxycodone causes miosis, even in total darkness. Pinpoint pupils are a sign of opioid overdose but are not pathognomonic (e.g., pontine lesions of hemorrhagic or ischemic origins may produce similar findings). Marked mydriasis rather than miosis may be seen due to hypoxia in overdose situations.

Therapeutic doses of acetaminophen have negligible effects on the cardiovascular or respiratory systems; however, toxic doses may cause circulatory failure and rapid, shallow breathing.

Effects on the Gastrointestinal Tract and Other Smooth Muscle

Oxycodone causes a reduction in motility associated with an increase in smooth muscle tone in the antrum of the stomach and duodenum. Digestion of food in the small intestine is delayed and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, while tone may be increased to the point of spasm, resulting in constipation. Other opioid-induced effects may include a reduction in biliary and pancreatic secretions, spasm of sphincter of Oddi, and transient elevations in serum amylase.

Effects on the Cardiovascular System

Oxycodone produces peripheral vasodilation which may result in orthostatic hypotension or syncope. Manifestations of histamine release and/or peripheral vasodilation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.

Effects on the Endocrine System

Opioids inhibit the secretion of adrenocorticotropic hormone (ACTH), cortisol, and luteinizing hormone (LH) in humans *[see ADVERSE REACTIONS]*. They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon.

Use of opioids for an extended period of time may influence the hypothalamic-pituitarygonadal axis, leading to androgen deficiency that may manifest as low libido, impotence, erectile dysfunction, amenorrhea, or infertility. The causal role of opioids in the syndrome of hypogonadism is unknown because the various medical, physical, lifestyle, and psychological stressors that may influence gonadal hormone levels have not been adequately controlled for in studies conducted to date [see ADVERSE REACTIONS].

Effects on the Immune System

Opioids have been shown to have a variety of effects on components of the immune system. The clinical significance of these findings is unknown. Overall, the effects of opioids appear to be modestly immunosuppressive.

Concentration-Efficacy Relationships

The minimum effective analgesic concentration will vary widely among patients, especially among patients who have been previously treated with opioid agonists. The minimum effective analgesic concentration of oxycodone for any individual patient may increase over time due to an increase in pain, the development of a new pain syndrome, and/or the development of analgesic tolerance [see DOSAGE AND ADMINISTRATION].

Concentration-Adverse Reaction Relationships

There is a relationship between increasing oxycodone plasma concentration and increasing frequency of dose-related opioid adverse reactions such as nausea, vomiting, CNS effects, and respiratory depression. In opioid-tolerant patients, the situation may be altered by the development of tolerance to opioid-related adverse reactions [see DOSAGE AND ADMINISTRATION].

Pharmacokinetics

Absorption and Distribution

The mean absolute oral bioavailability of oxycodone in cancer patients was reported to be about 87%. Oxycodone has been shown to be 45% bound to human plasma proteins *in vitro*. The volume of distribution after intravenous administration is 211.9 ±186.6 L.

Absorption of acetaminophen is rapid and almost complete from the GI tract after oral administration. With overdosage, absorption is complete in 4 hours. Acetaminophen is relatively uniformly distributed throughout most body fluids. Binding of the drug to plasma proteins is variable; only 20% to 50% may be bound at the concentrations encountered during acute intoxication.

Metabolism and Elimination

<u>Oxycodone</u>

In humans, oxycodone is extensively metabolized to noroxycodone by means of CYP3Amediated N- demethylation, oxymorphone by means of CYP2D6-mediated Odemethylation, and their glucuronides [see PRECAUTIONS; Drug Interactions].

<u>Acetaminophen</u>

Acetaminophen is rapidly absorbed from the gastrointestinal tract and is distributed throughout most body tissues. A small fraction (10 to 25%) of acetaminophen is bound to plasma proteins. The plasma half-life is 1.25 to 3 hours, but may be increased by liver damage and following overdosage. Elimination of acetaminophen is principally by liver metabolism (conjugation) and subsequent renal excretion of metabolites. Acetaminophen is primarily metabolized in the liver by first-order kinetics and involves three principal separate pathways: conjugation with glucuronide; conjugation with sulfate; and oxidation via the cytochrome, P450-dependent, mixed-function oxidase enzyme pathway to form a reactive intermediate metabolite, which conjugates with glutathione and is then further metabolized to form cysteine and mercapturic acid conjugates. The principal cytochrome P450 isoenzyme involved appears to be CYP2E1, with CYP1A2 and CYP3A4 as additional pathways. Approximately 85% of an oral dose appears in the urine within 24 hours of administration, most as the glucuronide conjugate, with small amounts of other conjugates and unchanged drug *[see OVERDOSAGE]* for toxicity information.

INDICATIONS AND USAGE

PERCOCET is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Limitations of Use:

Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration [see WARNINGS], reserve PERCOCET for use in patients for whom alternative treatment options (e.g., non-opioid analgesics):

- Have not been tolerated or are not expected to be tolerated,
- Have not provided adequate analgesia or are not expected to provide adequate analgesia

PERCOCET should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate.

CONTRAINDICATIONS

PERCOCET is contraindicated in patients with:

- Significant respiratory depression [see WARNINGS]
- Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see WARNINGS]
- Known or suspected gastrointestinal obstruction, including paralytic ileus [see WARNINGS]
- Hypersensitivity to oxycodone, acetaminophen, or any other component of the product (e.g., anaphylaxis) [see WARNINGS, ADVERSE REACTIONS]

WARNINGS

Addiction, Abuse, and Misuse

PERCOCET contains oxycodone, a Schedule II controlled substance. As an opioid, PERCOCET exposes users to the risks of addiction, abuse, and misuse [see DRUG ABUSE AND DEPENDENCE].

Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed PERCOCET. Addiction can occur at recommended dosages and if the drug is misused or abused.

Assess each patient's risk for opioid addiction, abuse, or misuse prior to prescribing PERCOCET, and reassess all patients receiving PERCOCET for the development of these behaviors and conditions. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). The potential for these risks should not, however, prevent the proper management of pain in any given patient. Patients at increased risk may be prescribed opioids such as PERCOCET, but use in such patients necessitates intensive counseling about the risks and proper use of PERCOCET along with frequent reevaluation for signs of addiction, abuse, and misuse. Consider prescribing naloxone

for the emergency treatment of opioid overdose [see WARNINGS; Life-Threatening Respiratory Depression, DOSAGE AND ADMINISTRATION; Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose].

Opioids are sought for nonmedical use and are subject to diversion from legitimate prescribed use. Consider these risks when prescribing or dispensing PERCOCET. Strategies to reduce these risks include prescribing the drug in the smallest appropriate quantity and advising the patient on careful storage of the drug during the course of treatment and proper disposal of unused drug [see PRECAUTIONS; Information for Patients/Caregivers]. Contact local state professional licensing board or state-controlled substances authority for information on how to prevent and detect abuse or diversion of this product.

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even when used as recommended. Respiratory depression, if not immediately recognized and treated, may lead to respiratory arrest and death. Management of respiratory depression may include close observation, supportive measures, and use of opioid antagonists, depending on the patient's clinical status [see OVERDOSAGE]. Carbon dioxide (CO_2) retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids.

While serious, life-threatening, or fatal respiratory depression can occur at any time during the use of PERCOCET, the risk is greatest during the initiation of therapy or following a dosage increase.

To reduce the risk of respiratory depression, proper dosing and titration of PERCOCET are essential [see DOSAGE AND ADMINISTRATION]. Overestimating the PERCOCET dosage when converting patients from another opioid product can result in a fatal overdose with the first dose.

Accidental ingestion of even one dose of PERCOCET, especially by children, can result in respiratory depression and death due to an overdose of oxycodone.

Educate patients and caregivers on how to recognize respiratory depression and emphasize the importance of calling 911 or getting emergency medical help right away in the event of a known or suspected overdose [see PRECAUTIONS; Information for Patients/Caregivers].

Opioids can cause sleep-related breathing disorders including central sleep apnea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present with CSA, consider decreasing the opioid dosage using best practices for opioid taper [see DOSAGE AND ADMINISTRATION].

Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose

Discuss the availability of naloxone for the emergency treatment of opioid overdose with the patient and caregiver and assess the potential need for access to naloxone, both when initiating and renewing treatment with PERCOCET.

Inform patients and caregivers about the various ways to obtain naloxone as permitted by individual state naloxone dispensing and prescribing requirements or guidelines (e.g., by prescription, directly from a pharmacist, or as part of a community-based program). Educate patients and caregivers on how to recognize respiratory depression and emphasize the importance of calling 911 or getting emergency medical help, even if naloxone is administered [see PRECAUTIONS; Information for Patients/Caregivers].

Consider prescribing naloxone, based on the patient's risk factors for overdose, such as concomitant use of CNS depressants, a history of opioid use disorder, or prior opioid overdose. The presence of risk factors for overdose should not prevent the proper management of pain in any given patient. Also consider prescribing naloxone if the patient has household members (including children) or other close contacts at risk for accidental ingestion or overdose. If naloxone is prescribed, educate patients and caregivers on how to treat with naloxone [see DOSAGE AND ADMINISTRATION, Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose; WARNINGS; Addiction, Abuse, and Misuse, Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants, PRECAUTIONS; Information for Patients/Caregivers, OVERDOSAGE].

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants

Profound sedation, respiratory depression, coma, and death may result from the concomitant use of PERCOCET with benzodiazepines and/or other CNS depressants, including alcohol (e.g., non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids). Because of these risks, reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate.

Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioid analgesics alone. Because of similar pharmacological properties, it is reasonable to expect similar risk with the concomitant use of other CNS depressant drugs with opioid analgesics [see PRECAUTIONS; Drug Interactions].

If the decision is made to prescribe a benzodiazepine or other CNS depressant concomitantly with an opioid analgesic, prescribe the lowest effective dosages and minimum durations of concomitant use. In patients already receiving an opioid analgesic, prescribe a lower initial dose of the benzodiazepine or other CNS depressant than indicated in the absence of an opioid, and titrate based on clinical response. If an opioid analgesic is initiated in a patient already taking a benzodiazepine or other CNS depressant, prescribe a lower initial dose of the opioid analgesic, and titrate based on clinical response. Inform patients and caregivers of this potential interaction, educate them on the signs and symptoms of respiratory depression (including sedation).

If concomitant use is warranted, consider prescribing naloxone for the emergency treatment of opioid overdose [see WARNINGS; Life-Threatening Respiratory Depression, DOSAGE AND ADMINISTRATION; Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose].

Advise both patients and caregivers about the risks of respiratory depression and sedation when PERCOCET is used with benzodiazepines or other CNS depressants (including alcohol and illicit drugs). Advise patients not to drive or operate heavy machinery until the effects of concomitant use of the benzodiazepine or other CNS depressant have been determined. Screen patients for risk of substance use disorders, including opioid abuse and misuse, and warn them of the risk for overdose and death associated with the use of additional CNS depressants including alcohol and illicit drugs.

Neonatal Opioid Withdrawal Syndrome

Use of PERCOCET for an extended period of time during pregnancy can result in withdrawal in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal syndrome in adults, may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. Observe newborns for signs of neonatal opioid withdrawal syndrome and manage accordingly. Advise pregnant women using opioids for an extended period of time of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available [see PRECAUTIONS; Information for Patients/Caregivers, Pregnancy].

Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)

To ensure that the benefits of opioid analgesics outweigh the risks of addiction, abuse, and misuse, the Food and Drug Administration (FDA) has required a Risk Evaluation and Mitigation Strategy (REMS) for these products. Under the requirements of the REMS, drug companies with approved opioid analgesic products must make REMS-compliant education programs available to healthcare providers. Healthcare providers are strongly encouraged to do all of the following:

- Complete a <u>REMS-compliant education program</u> offered by an accredited provider of continuing education (CE) or another education program that includes all the elements of the FDA Education Blueprint for Health Care Providers Involved in the Management or Support of Patients with Pain.
- Discuss the safe use, serious risks, and proper storage and disposal of opioid analgesics with patients and/or their caregivers every time these medicines are prescribed. The <u>Patient Counseling Guide (PCG)</u> can be obtained at this link: <u>www.fda.gov/OpioidAnalgesicREMSPCG</u>.
- Emphasize to patients and their caregivers the importance of reading the Medication Guide that they will receive from their pharmacist every time an opioid analgesic is dispensed to them.
- Consider using other tools to improve patient, household, and community safety, such as patient-prescriber agreements that reinforce patient-prescriber responsibilities.

To obtain further information on the opioid analgesic REMS and for a list of accredited REMS CME/CE, call 800-503-0784, or log on to <u>www.opioidanalgesicrems.com</u>. The FDA Blueprint can be found at <u>www.fda.gov/OpioidAnalgesicREMSBlueprint</u>.

Risks of Concomitant Use or Discontinuation of Cytochrome P450 3A4 Inhibitors and Inducers

Concomitant use of PERCOCET with a CYP3A4 inhibitor, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may increase plasma concentrations of oxycodone hydrochloride and prolong opioid adverse reactions, which may cause potentially fatal respiratory depression [see WARNINGS], particularly when an inhibitor is added after a stable dose of PERCOCET is achieved. Similarly, discontinuation of a CYP3A4 inducer, such as rifampin, carbamazepine, and phenytoin, in PERCOCET-treated patients may increase oxycodone plasma concentrations and prolong opioid adverse reactions. When

using PERCOCET with CYP3A4 inhibitors or discontinuing CYP3A4 inducers in PERCOCET-treated patients, evaluate patients at frequent intervals and consider dosage reduction of PERCOCET until stable drug effects are achieved [see PRECAUTIONS; Drug Interactions].

Concomitant use of PERCOCET with CYP3A4 inducers or discontinuation of an CYP3A4 inhibitor could decrease oxycodone hydrochloride plasma concentrations, decrease opioid efficacy or, possibly, lead to a withdrawal syndrome in a patient who had developed physical dependence to oxycodone hydrochloride. When using PERCOCET with CYP3A4 inducers or discontinuing CYP3A4 inhibitors, monitor patients closely at frequent intervals and consider increasing the opioid dosage if needed to maintain adequate analgesia or if symptoms of opioid withdrawal occur [see PRECAUTIONS; Drug Interactions].

Hepatotoxicity

Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 milligrams per day, and often involve more than one acetaminophen-containing product. The excessive intake of acetaminophen may be intentional to cause self-harm or unintentional as patients attempt to obtain more pain relief or unknowingly take other acetaminophen-containing products.

The risk of acute liver failure is higher in individuals with underlying liver disease and in individuals who ingest alcohol while taking acetaminophen.

Instruct patients to look for acetaminophen or APAP on package labels and not to use more than one product that contains acetaminophen. Instruct patients to seek medical attention immediately upon ingestion of more than 4000 milligrams of acetaminophen per day, even if they feel well.

Opioid-Induced Hyperalgesia and Allodynia

Opioid-Induced Hyperalgesia (OIH) occurs when an opioid analgesic paradoxically causes an increase in pain, or an increase in sensitivity to pain. This condition differs from tolerance, which is the need for increasing doses of opioids to maintain a defined effect [see DRUG ABUSE AND DEPENDENCE; Dependence]. Symptoms of OIH include (but may not be limited to) increased levels of pain upon opioid dosage increase, decreased levels of pain upon opioid dosage decrease, or pain from ordinarily nonpainful stimuli (allodynia). These symptoms may suggest OIH only if there is no evidence of underlying disease progression, opioid tolerance, opioid withdrawal, or addictive behavior.

Cases of OIH have been reported, both with short-term and longer-term use of opioid analgesics. Though the mechanism of OIH is not fully understood, multiple biochemical pathways have been implicated. Medical literature suggests a strong biologic plausibility between opioid analgesics and OIH and allodynia. If a patient is suspected to be experiencing OIH, carefully consider appropriately decreasing the dose of the current opioid analgesic or opioid rotation (safely switching the patient to a different opioid moiety) [see DOSAGE AND ADMINISTRATION, WARNINGS].

Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients

The use of PERCOCET in patients with acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment is contraindicated.

<u>Patients with Chronic Pulmonary Disease</u>: PERCOCET-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression are at increased risk of decreased respiratory drive including apnea, even at recommended dosages of PERCOCET [see WARNINGS; Life-Threatening Respiratory Depression].

<u>Elderly, Cachetic, or Debilitated Patients</u>: Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients because they may have altered pharmacokinetics or altered clearance compared to younger, healthier patients [see WARNINGS; Life-Threatening Respiratory Depression].

Regularly evaluate patients, particularly when initiating and titrating PERCOCET and when PERCOCET is given concomitantly with other drugs that depress respiration [see WARNINGS; Life-Threatening Respiratory Depression]. Alternatively, consider the use of non-opioid analgesics in these patients.

Adrenal Insufficiency

Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use. Presentation of adrenal insufficiency may include non-specific symptoms and signs including nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. If adrenal insufficiency is suspected, confirm the diagnosis with diagnostic testing as soon as possible. If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. Wean the patient off of the opioid to allow adrenal function to recover and continue corticosteroid treatment until adrenal function recovers. Other opioids may be tried as some cases reported use of a different opioid without recurrence of adrenal insufficiency. The information available does not identify any particular opioids as being more likely to be associated with adrenal insufficiency.

Severe Hypotension

PERCOCET may cause severe hypotension including orthostatic hypotension and syncope in ambulatory patients. There is increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g., phenothiazines or general anesthetics) [see PRECAUTIONS; Drug Interactions]. Regularly evaluate these patients for signs of hypotension after initiating or titrating the dosage of PERCOCET. In patients with circulatory shock PERCOCET may cause vasodilatation that can further reduce cardiac output and blood pressure. Avoid the use of PERCOCET with circulatory shock.

Serious Skin Reactions

Rarely, acetaminophen may cause serious skin reactions such as acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. Patients should be informed about the signs of serious skin reactions, and use of the drug should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity.

Hypersensitivity/Anaphylaxis

There have been post-marketing reports of hypersensitivity and anaphylaxis associated with use of acetaminophen. Clinical signs included swelling of the face, mouth, and throat, respiratory distress, urticaria, rash, pruritus, and vomiting. There were infrequent reports of life-threatening anaphylaxis requiring emergency medical attention. Instruct patients to discontinue PERCOCET immediately and seek medical care if they experience these symptoms. Do not prescribe PERCOCET for patients with acetaminophen allergy [see PRECAUTIONS; Information for Patients/Caregivers].

Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness

In patients who may be susceptible to the intracranial effects of CO_2 retention (e.g., those with evidence of increased intracranial pressure or brain tumors), PERCOCET may reduce respiratory drive, and the resultant CO_2 retention can further increase intracranial pressure. Monitor such patients for signs of sedation and respiratory depression, particularly when initiating therapy with PERCOCET.

Opioids may also obscure the clinical course in a patient with a head injury. Avoid the use of PERCOCET in patients with impaired consciousness or coma.

Risks of Use in Patients with Gastrointestinal Conditions

PERCOCET are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.

The administration of PERCOCET, or other opioids may obscure the diagnosis or clinical course in patients with acute abdominal conditions.

The oxycodone in PERCOCET may cause spasm of the sphincter of Oddi. Opioids may cause increases in serum amylase. Regularly evaluate patients with biliary tract disease, including acute pancreatitis, for worsening symptoms.

Increased Risk of Seizures in Patients with Seizure Disorders

The oxycodone in PERCOCET may increase the frequency of seizures in patients with seizure disorders, and may increase the risk of seizures occurring in other clinical settings associated with seizures. Regularly evaluate patients with a history of seizure disorders for worsened seizure control during PERCOCET therapy.

Withdrawal

Do not abruptly discontinue PERCOCET in a patient physically dependent on opioids. When discontinuing PERCOCET in a physically dependent patient, gradually taper the dosage. Rapid tapering of PERCOCET in a patient physically dependent on opioids may lead to a withdrawal syndrome and return of pain [see DOSAGE AND ADMINISTRATION, DRUG ABUSE AND DEPENDENCE].

Additionally, avoid the use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g., buprenorphine) analgesics in patients who are receiving a full opioid agonist analgesic, including PERCOCET. In these patients, mixed agonist/antagonist and partial agonist analgesics may reduce the analgesic effect and/or precipitate withdrawal symptoms [see PRECAUTIONS; Drug Interactions].

Risks of Driving and Operating Machinery

PERCOCET may impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery. Warn patients not to drive or operate dangerous machinery unless they are tolerant to the effects of PERCOCET and know how they will react to the medication [see PRECAUTIONS; Information for Patients/Caregivers].

PRECAUTIONS

Information for Patients/Caregivers

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Storage and Disposal

Because of the risks associated with accidental ingestion, misuse, and abuse, advise patients to store PERCOCET securely, out of sight and reach of children and in a location not accessible by others, including visitors to the home. Inform patients that leaving PERCOCET unsecured can pose a deadly risk to others in the home [see WARNINGS, DRUG ABUSE AND DEPENDENCE].

Advise patients and caregivers that when medicines are no longer needed, they should be disposed of promptly. Expired, unwanted, or unused PERCOCET should be disposed of by flushing the unused medication down the toilet if a drug take-back option is not readily available. Inform patients that they can visit www.fda.gov/drugdisposal for a complete list of medicines recommended for disposal by flushing, as well as additional information on disposal of unused medicines.

Addiction, Abuse, and Misuse

Inform patients that the use of PERCOCET, even when taken as recommended, can result in addiction, abuse, and misuse, which can lead to overdose and death [see WARNINGS]. Instruct patients not to share PERCOCET with others and to take steps to protect PERCOCET from theft or misuse.

Life-Threatening Respiratory Depression

Inform patients of the risk of life-threatening respiratory depression, including information that the risk is greatest when starting PERCOCET or when the dosage is increased, and that it can occur even at recommended dosages.

Educate patients and caregivers on how to recognize respiratory depression and emphasize the importance of calling 911 or getting emergency medical help right away in the event of a known or suspected overdose [see WARNINGS; Life-Threatening Respiratory Depression].

Accidental Ingestion

Inform patients that accidental ingestion, especially by children, may result in respiratory depression or death [see WARNINGS].

Interactions with Benzodiazepines and Other CNS Depressants

Inform patients and caregivers that potentially fatal additive effects may occur if PERCOCET are used with benzodiazepines and other CNS depressants, including alcohol, and not to use these concomitantly unless supervised by a health care provider [see WARNINGS, PRECAUTIONS; Drug Interactions].

Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose

Discuss with the patient and caregiver the availability of naloxone for the emergency treatment of opioid overdose, both when initiating and renewing treatment with PERCOCET. Inform patients and caregivers about the various ways to obtain naloxone as permitted by individual state naloxone dispensing and prescribing requirements or guidelines (e.g., by prescription, directly from a pharmacist, or as part of a community-based program) [see WARNINGS; Life-Threatening Respiratory Depression, DOSAGE AND ADMINISTRATION].

Educate patients and caregivers on how to recognize the signs and symptoms of an overdose.

Explain to patients and caregivers that naloxone's effects are temporary, and that they must call 911 or get emergency medical help right away in all cases of known or suspected opioid overdose, even if naloxone is administered [see OVERDOSAGE].

If naloxone is prescribed, also advise patients and caregivers:

- How to treat with naloxone in the event of an opioid overdose
- To tell family and friends about their naloxone and to keep it in a place where family and friends can access it in an emergency
- To read the Patient Information (or other educational material) that will come with their naloxone. Emphasize the importance of doing this before an opioid emergency happens, so the patient and caregiver will know what to do.

Hyperalgesia and Allodynia

Inform patients and caregivers not to increase opioid dosage without first consulting a clinician. Advise patients to seek medical attention if they experience symptoms of hyperalgesia, including worsening pain, increased sensitivity to pain, or new pain [see WARNINGS; ADVERSE REACTIONS].

Serotonin Syndrome

Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. Warn patients of the symptoms of serotonin syndrome and to seek medical attention right away if symptoms develop. Instruct patients to inform their healthcare providers if they are taking, or plan to take serotonergic medications [see PRECAUTIONS; Drug Interactions].

Monoamine Oxidase Inhibitor (MAOI) Interaction

Inform patients to avoid taking PERCOCET while using any drugs that inhibit monoamine oxidase. Patients should not start MAOIs while taking PERCOCET Tablets [see PRECAUTIONS; Drug Interactions].

Important Administration Instructions

Instruct patients how to properly take PERCOCET [see DOSAGE AND ADMINISTRATION, WARNINGS].

Advise patients not to adjust the medication dose themselves and to consult with their healthcare provider prior to any dosage adjustment.

Advise patients who are treated with PERCOCET for more than a few weeks not to abruptly discontinue the medication. Advise patients to consult with their physician for a gradual discontinuation dose schedule to taper off the medication.

Important Discontinuation Instructions

In order to avoid developing withdrawal symptoms, instruct patients not to discontinue PERCOCET without first discussing a tapering plan with the prescriber [see DOSAGE AND ADMINISTRATION].

Maximum Daily Dose of Acetaminophen

Inform patients to not take more than 4000 milligrams of acetaminophen per day. Advise patients to call their prescriber if they take more than the recommended dose.

Driving or Operating Heavy Machinery

Inform patients that PERCOCET may impair the ability to perform potentially hazardous activities such as driving a car or operating heavy machinery. Advise patients not to perform such tasks until they know how they will react to the medication [see PRECAUTIONS].

Constipation

Advise patients of the potential for severe constipation, including management instructions and when to seek medical attention [see ADVERSE REACTIONS, CLINICAL PHARMACOLOGY].

Adrenal Insufficiency

Inform patients that opioids could cause adrenal insufficiency, a potentially lifethreatening condition. Adrenal insufficiency may present with non-specific symptoms and signs such as nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. Advise patients to seek medical attention if they experience a constellation of these symptoms *[see WARNINGS]*.

Hypotension

Inform patients that PERCOCET may cause orthostatic hypotension and syncope. Instruct patients how to recognize symptoms of low blood pressure and how to reduce the risk of serious consequences should hypotension occur (e.g., sit or lie down, carefully rise from a sitting or lying position) *[see WARNINGS]*.

<u>Anaphylaxis</u>

Inform patients that anaphylaxis have been reported with ingredients contained in PERCOCET. Advise patients how to recognize such a reaction and when to seek medical attention [see CONTRAINDICATIONS, ADVERSE REACTIONS].

<u>Pregnancy</u>

Neonatal Opioid Withdrawal Syndrome

Inform female patients of reproductive potential that use of PERCOCET for an extended period of time during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated [see WARNINGS,

PRECAUTIONS; Pregnancy].

Embryo-Fetal Toxicity

Inform female patients of reproductive potential that PERCOCET can cause fetal harm and to inform the healthcare provider of a known or suspected pregnancy [see PRECAUTIONS; Pregnancy].

Lactation

Advise breastfeeding women using PERCOCET to carefully observe infants for increased sleepiness (more than usual), breathing difficulties, or limpness. Instruct breastfeeding women to seek immediate medical care if they notice these signs [see PRECAUTIONS; Nursing Mothers].

Infertility

Inform patients that use of opioids for an extended period of time may cause reduced fertility. It is not known whether these effects on fertility are reversible [see ADVERSE REACTIONS].

Laboratory Tests

Although oxycodone may cross-react with some drug urine tests, no available studies were found which determined the duration of detectability of oxycodone in urine drug screens. However, based on pharmacokinetic data, the approximate duration of detectability for a single dose of oxycodone is roughly estimated to be one to two days following drug exposure.

Urine testing for opiates may be performed to determine illicit drug use and for medical reasons such as evaluation of patients with altered states of consciousness or monitoring efficacy of drug rehabilitation efforts. The preliminary identification of opiates in urine involves the use of an immunoassay screening and thin-layer chromatography (TLC). Gas chromatography/mass spectrometry (GC/MS) may be utilized as a third-stage identification step in the medical investigational sequence for opiate testing after immunoassay and TLC. The identities of 6-keto opiates (e.g., oxycodone) can further be differentiated by the analysis of their methoximetrimethylsilyl (MO-TMS) derivative.

Drug Interactions

Inhibitors of CYP3A4 and CYP2D6

The concomitant use of PERCOCET and CYP3A4 inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g. ketoconazole), and protease inhibitors (e.g., ritonavir), can increase the plasma concentration of oxycodone, resulting in increased or prolonged opioid effects. These effects could be more pronounced with concomitant use of PERCOCET and CYP3A4 and CYP2D6 inhibitors, particularly when an inhibitor is added after a stable dose of PERCOCET is achieved [see WARNINGS].

After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the oxycodone plasma concentration will decrease [*see CLINICAL PHARMACOLOGY*], resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to PERCOCET.

If concomitant use is necessary, consider dosage reduction of PERCOCET until stable drug effects are achieved. Evaluate patients at frequent intervals for respiratory

depression and sedation. If a CYP3A4 inhibitor is discontinued, consider increasing the PERCOCET dosage until stable drug effects are achieved. Evaluate for signs of opioid withdrawal.

Inducers of CYP3A4

The concomitant use of PERCOCET and CYP3A4 inducers, such as rifampin, carbamazepine, and phenytoin, can decrease the plasma concentration of oxycodone *[see CLINICAL PHARMACOLOGY]*, resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to PERCOCET *[see WARNINGS]*.

After stopping a CYP3A4 inducer, as the effects of the inducer decline, the oxycodone plasma concentration will increase *[see CLINICAL PHARMACOLOGY]*, which could increase or prolong both the therapeutic effects and adverse reactions, and may cause serious respiratory depression.

If concomitant use is necessary, consider increasing the PERCOCET dosage until stable drug effects are achieved. Evaluate for signs of opioid withdrawal. If a CYP3A4 inducer is discontinued, consider PERCOCET dosage reduction and evaluate patients at frequent intervals for signs of respiratory depression and sedation.

Benzodiazepines and Other CNS Depressants

Due to additive pharmacologic effect, the concomitant use of benzodiazepines and other CNS depressants such as benzodiazepines and other sedative hypnotics, anxiolytics, and tranquilizers, muscle relaxants, general anesthetics, antipsychotics, and other opioids, including alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death.

Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Inform patients and caregivers of this potential interaction, educate them on the signs and symptoms of respiratory depression (including sedation). If concomitant use is warranted, consider prescribing naloxone for the emergency treatment of opioid overdose [see WARNINGS].

Serotonergic Drugs

The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tryptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers].

If concomitant use is warranted, frequently evaluate the patient, particularly during treatment initiation and dose adjustment. Discontinue PERCOCET if serotonin syndrome is suspected.

Monoamine Oxidase Inhibitors (MAOIs)

The concomitant use of opioids and MAOIs, such as phenelzine, tranylcypromine,

linezolid, may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) *[see WARNINGS]*.

The use of PERCOCET is not recommended for patients taking MAOIs or within 14 days of stopping such treatment.

If urgent use of an opioid is necessary, use test doses and frequent titration of small doses to treat pain while closely monitoring blood pressure and signs and symptoms of CNS and respiratory depression.

Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics

The concomitant use of opioids with other opioid analgesics, such as butorphanol, nalbuphine, pentazocine, may reduce the analgesic effect of PERCOCET and/or precipitate withdrawal symptoms.

Advise patient to avoid concomitant use of these drugs.

Muscle Relaxants

PERCOCET may enhance the neuromuscular-blocking action of skeletal muscle relaxants and produce an increase in the degree of respiratory depression.

Because respiratory depression may be greater than otherwise expected, decrease the dosage of PERCOCET and/or the muscle relaxant as necessary. Due to the risk of respiratory depression with concomitant use of skeletal muscle relaxants and opioids, consider prescribing naloxone for the emergency treatment of opioid overdose [see WARNINGS].

<u>Diuretics</u>

Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.

Evaluate patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed.

Anticholinergic Drugs

The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.

Evaluate patients for signs of urinary retention or reduced gastric motility when PERCOCET is used concomitantly with anticholinergic drugs.

<u>Alcohol, ethyl</u>

Hepatotoxicity has occurred in chronic alcoholics following various dose levels (moderate to excessive) of acetaminophen.

Oral Contraceptives

Increase in glucuronidation resulting in increased plasma clearance and a decreased half-life of acetaminophen.

Charcoal (activated)

Reduces acetaminophen absorption when administered as soon as possible after overdose.

Beta Blockers (Propranolol)

Propranolol appears to inhibit the enzyme systems responsible for the glucuronidation and oxidation of acetaminophen. Therefore, the pharmacologic effects of acetaminophen may be increased.

Loop Diuretics

The effects of the loop diuretic may be decreased because acetaminophen may decrease renal prostaglandin excretion and decrease plasma renin activity.

Lamotrigine

Serum lamotrigine concentrations may be reduced, producing a decrease in therapeutic effects.

Probenecid

Probenecid may increase the therapeutic effectiveness of acetaminophen slightly.

Zidovudine

The pharmacologic effects of zidovudine may be decreased because of enhanced nonhepatic or renal clearance of zidovudine.

Drug/Laboratory Test Interactions

Depending on the sensitivity/specificity and the test methodology, the individual components of PERCOCET may cross-react with assays used in the preliminary detection of cocaine (primary urinary metabolite, benzoylecgonine) or marijuana (cannabinoids) in human urine. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. The preferred confirmatory method is gas chromatography/mass spectrometry (GC/MS). Moreover, clinical considerations and professional judgment should be applied to any drug-of-abuse test result, particularly when preliminary positive results are used.

Acetaminophen may interfere with home blood glucose measurement systems; decreases of >20% in mean glucose values may be noted. This effect appears to be drug, concentration and system dependent.

Carcinogenesis, Mutagenesis, Impairment of Fertility

<u>Carcinogenesis</u>

Long-term studies to evaluate the carcinogenic potential of the combination of Oxycodone Hydrochloride and Acetaminophen have not been conducted.

Long-term studies in mice and rats have been completed by the National Toxicology Program to evaluate the carcinogenic potential of acetaminophen. In 2-year feeding studies, F344/N rats and B6C3F1 mice were fed a diet containing acetaminophen up to 6000 ppm. Female rats demonstrated equivocal evidence of carcinogenic activity based on increased incidences of mononuclear cell leukemia at 0.8 times the maximum human daily dose (MHDD) of 4 grams/day, based on a body surface area comparison. In contrast, there was no evidence of carcinogenic activity in male rats that received up to 0.7 times or mice at up to 1.2 to 1.4 times the MHDD, based on a body surface area comparison.

<u>Mutagenesis</u>

The combination of Oxycodone Hydrochloride and Acetaminophen has not been evaluated for mutagenicity. Oxycodone alone was negative in a bacterial reverse mutation assay (Ames), an *in vitro* chromosome aberration assay with human lymphocytes without metabolic activation and an *in vivo* mouse micronucleus assay. Oxycodone was clastogenic in the human lymphocyte chromosomal assay in the presence of metabolic activation and in the mouse lymphoma assay with or without metabolic activation.

In the published literature, acetaminophen has been reported to be clastogenic when administered at 1500 mg/kg/day to the rat model (3.6-times the MHDD, based on a body surface area comparison). In contrast, no clastogenicity was noted at a dose of 750 mg/kg/day (1.8-times the MHDD, based on a body surface area comparison), suggesting a threshold effect.

Impairment of Fertility

In studies conducted by the National Toxicology Program, fertility assessments with acetaminophen have been completed in Swiss CD-1 mice via a continuous breeding study. There were no effects on fertility parameters in mice consuming up to 1.7 times the MHDD of acetaminophen, based on a body surface area comparison. Although there was no effect on sperm motility or sperm density in the epididymis, there was a significant increase in the percentage of abnormal sperm in mice consuming 1.78 times the MHDD (based on a body surface comparison) and there was a reduction in the number of mating pairs producing a fifth litter at this dose, suggesting the potential for cumulative toxicity with chronic administration of acetaminophen near the upper limit of daily dosing.

Published studies in rodents report that oral acetaminophen treatment of male animals at doses that are 1.2 times the MHDD and greater (based on a body surface comparison) result in decreased testicular weights, reduced spermatogenesis, reduced fertility, and reduced implantation sites in females given the same doses. These effects appear to increase with the duration of treatment. The clinical significance of these findings is not known.

Infertility

Use of opioids for an extended period of time may cause reduced fertility in females and males of reproductive potential. It is not known whether these effects on fertility are reversible [see ADVERSE REACTIONS].

Pregnancy

Teratogenic Effects

Animal reproductive studies have not been conducted with PERCOCET. It is also not known whether PERCOCET can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. PERCOCET should not be given to a pregnant woman unless in the judgment of the physician, the potential benefits outweigh the possible hazards.

Nonteratogenic Effects

Fetal/Neonatal Adverse Reactions

Use of opioid analgesics for an extended period of time during pregnancy for medical or nonmedical purposes can result in physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth.

Neonatal opioid withdrawal syndrome presents as irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea and failure to gain weight. The onset, duration, and severity of neonatal opioid withdrawal syndrome vary based on the specific opioid used, duration of use, timing and amount of last maternal use, and rate of elimination of the drug by the newborn. Observe newborns for symptoms of neonatal opioid withdrawal syndrome syndrome and manage accordingly [see WARNINGS].

Labor or Delivery

Opioids cross the placenta and may produce respiratory depression and psychophysiologic effects in neonates. An opioid antagonist, such as naloxone, must be available for reversal of opioid-induced respiratory depression in the neonate. PERCOCET is not recommended for use in pregnant women during or immediately prior to labor, when other analgesic techniques are more appropriate. Opioid analgesics, including PERCOCET, can prolong labor through actions which temporarily reduce the strength, duration, and frequency of uterine contractions. However, this effect is not consistent and may be offset by an increased rate of cervical dilation, which tends to shorten labor. Monitor neonates exposed to opioid analgesics during labor for signs of excess sedation and respiratory depression.

Nursing Mothers

Available data from lactation studies indicate that oxycodone is present in breastmilk and that doses of less than 60 mg/day of the immediate-release formulation are unlikely to result in clinically relevant exposures in breastfed infants. A pharmacokinetics study utilizing opportunistic sampling of 76 lactating women receiving oxycodone immediate-release products for postpartum pain management showed that oxycodone concentrates in breastmilk with an average milk to plasma ratio of 3.2. The relative infant dose was low, approximately 1.3% of a weight-adjusted maternal dose (*see Data*).

In the same study, among the 70 infants exposed to oxycodone in breastmilk, no adverse events were attributed to oxycodone. However, based on known adverse effects in adults, infants should be monitored for signs of excess sedation and respiratory depression (*see Clinical Considerations*). There are no data on the effects of the oxycodone on milk production.

Acetaminophen is also excreted in breast milk in low concentrations.

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for PERCOCET and any potential adverse effects on the breastfed infant from PERCOCET or from the underlying maternal condition.

Infants exposed to PERCOCET through breast milk should be monitored for excess sedation and respiratory depression. Withdrawal symptoms can occur in breastfed infants when maternal administration of an opioid analgesic is stopped, or when breastfeeding is stopped.

Data

Oxycodone concentration data from 76 lactating women receiving immediate-release oxycodone products for postpartum pain management, and 28 infants exposed to oxycodone in breastmilk showed that following a median (range) dose of oxycodone in mothers of 9.2 (5-10) mg/dose or 33.0 (5.4-59.3) mg/day, oxycodone concentrated in breastmilk with a median (range) milk to plasma ratio of 3.2 (1.2-5.3). However, when using maternal breastmilk data to estimate the daily and relative infant dose, the infant dose was 0.006 mg/kg/day, which is 1.3% of a weight-adjusted maternal dose of 10 mg every 6 hours. These estimates based on maternal breastmilk concentrations were corroborated by the observed infant concentrations, of which over 75% (19/25) were below the limit of quantification. Among the 6 infants with quantifiable concentration, the median (range) concentration was 0.2 ng/mL (0.1-0.7). These concentrations are 100 to 1000 times lower than concentrations observed in other studies after infants received oxycodone at 0.1 mg/kg/dose (~20-200 ng/mL).

Pediatric Use

Safety and effectiveness of PERCOCET in pediatric patients have not been established.

Geriatric Use

Elderly patients (aged 65 years or older) may have increased sensitivity PERCOCET. In general, use caution when selecting a dosage for an elderly patient, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.

Respiratory depression is the chief risk for elderly patients treated with opioids, and has occurred after large initial doses were administered to patients who were not opioidtolerant or when opioids were co- administered with other agents that depress respiration. Titrate the dosage of PERCOCET slowly in geriatric patients and frequently reevaluate the patient for signs of central nervous system and respiratory depression [see WARNINGS].

These drugs are known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to regularly evaluate renal function.

Hepatic Impairment

In a pharmacokinetic study of oxycodone in patients with end-stage liver disease, oxycodone plasma clearance decreased and the elimination half-life increased.

Because oxycodone is extensively metabolized in the liver, its clearance may decrease in patients with hepatic impairment. Initiate therapy in these patients with a lower than usual dosage of PERCOCET and titrate carefully. Regularly evaluate for adverse events such as respiratory depression, sedation, and hypotension [see CLINICAL PHARMACOLOGY].

Renal Impairment

In a study of patients with end stage renal impairment, mean elimination half-life was prolonged in uremic patients due to increased volume of distribution and reduced clearance. Oxycodone should be used with caution in patients with renal impairment. Because oxycodone is known to be substantially excreted by the kidney, its clearance may decrease in patients with renal impairment. Initiate therapy with a lower than usual dosage of PERCOCET and titrate carefully. Regularly evaluate for adverse events such as respiratory depression, sedation, and hypotension [see CLINICAL PHARMACOLOGY].

ADVERSE REACTIONS

The following adverse reactions have been identified during post approval use of PERCOCET. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Serious adverse reactions that may be associated with oxycodone and acetaminophen use include respiratory depression, apnea, respiratory arrest, circulatory depression, hypotension, and shock [see OVERDOSAGE].

The most frequently observed non-serious adverse reactions include lightheadedness, dizziness, drowsiness or sedation, nausea, and vomiting. These effects seem to be more prominent in ambulatory than in nonambulatory patients, and some of these adverse reactions may be alleviated if the patient lies down. Other adverse reactions include euphoria, dysphoria, constipation, and pruritus.

Hypersensitivity reactions may include: Skin eruptions, urticarial, erythematous skin reactions. Hematologic reactions may include: thrombocytopenia, neutropenia, pancytopenia, hemolytic anemia. Rare cases of agranulocytosis have likewise been associated with acetaminophen use. In high doses, the most serious adverse effect is a dose-dependent, potentially fatal hepatic necrosis. Renal tubular necrosis and hypoglycemic coma also may occur.

Other adverse reactions obtained from postmarketing experiences with oxycodone and acetaminophen are listed by organ system and in decreasing order of severity and/or frequency as follows:

Body as a Whole: Anaphylactoid reaction, allergic reaction, malaise, asthenia, fatigue, chest pain, fever, hypothermia, thirst, headache, increased sweating, accidental overdose, non-accidental overdose

Cardiovascular: Hypotension, hypertension, tachycardia, orthostatic hypotension, bradycardia, palpitations, dysrhythmias

Central and Peripheral Nervous System: Stupor, tremor, paraesthesia, hypoaesthesia, lethargy, seizures, anxiety, mental impairment, agitation, cerebral edema, confusion, dizziness

Fluid and Electrolyte: Dehydration, hyperkalemia, metabolic acidosis, respiratory alkalosis

Gastrointestinal: Dyspepsia, taste disturbances, abdominal pain, abdominal distention, sweating increased, diarrhea, dry mouth, flatulence, gastrointestinal disorder, nausea, vomiting, pancreatitis, intestinal obstruction, ileus

Hepatic: Transient elevations of hepatic enzymes, increase in bilirubin, hepatitis, hepatic failure, jaundice, hepatotoxicity, hepatic disorder

Hearing and Vestibular: Hearing loss, tinnitus

Hematologic: Thrombocytopenia

Hypersensitivity: Acute anaphylaxis, angioedema, asthma, bronchospasm, laryngeal edema, urticaria, anaphylactoid reaction

Metabolic and Nutritional: Hypoglycemia, hyperglycemia, acidosis, alkalosis

Musculoskeletal: Myalgia, rhabdomyolysis

Ocular: Miosis, visual disturbances, red eye

Psychiatric: Drug dependence, drug abuse, insomnia, confusion, anxiety, agitation, depressed level of consciousness, nervousness, hallucination, somnolence, depression, suicide

Respiratory System: Bronchospasm, dyspnea, hyperpnea, pulmonary edema, tachypnea, aspiration, hypoventilation, laryngeal edema

Skin and Appendages: Erythema, urticaria, rash, flushing

Urogenital: Interstitial nephritis, papillary necrosis, proteinuria, renal insufficiency and failure, urinary retention

- <u>Serotonin syndrome</u>: Cases of serotonin syndrome, a potentially life-threatening condition, have been reported during concomitant use of opioids with serotonergic drugs.
- <u>Adrenal insufficiency</u>: Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use.
- <u>Anaphylaxis</u>: Anaphylaxis has been reported with ingredients contained in PERCOCET.
- <u>Androgen deficiency</u>: Cases of androgen deficiency have occurred with use of opioids for an extended period of time [see CLINICAL PHARMACOLOGY].
- <u>Hyperalgesia and Allodynia</u>: Cases of hyperalgesia and allodynia have been reported with opioid therapy of any duration [see WARNINGS].
- <u>Hypoglycemia</u>: Cases of hypoglycemia have been reported in patients taking opioids. Most reports were in patients with at least one predisposing risk factor (e.g., diabetes).

DRUG ABUSE AND DEPENDENCE

Controlled Substance

PERCOCET contains oxycodone, a Schedule II controlled substance.

Abuse

PERCOCET contains oxycodone, a substance with high potential for misuse and abuse, which can lead to the development of substance use disorder, including addiction [see WARNINGS].

Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a healthcare provider or for whom it was not prescribed.

Abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects.

Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that

may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence.

Misuse and abuse of PERCOCET increases risk of overdose, which may lead to central nervous system and respiratory depression, hypotension, seizures, and death. The risk is increased with concurrent abuse of PERCOCET with alcohol and other CNS depressants. Abuse of and addiction to opioids in some individuals may not be accompanied by concurrent tolerance and symptoms of physical dependence. In addition, abuse of opioids can occur in the absence of addiction.

All patients treated with opioids require careful and frequent reevaluation for signs of misuse, abuse, and addiction, because use of opioid analgesic products carries the risk of addiction even under appropriate medical use. Patients at high risk of PERCOCET abuse include those with a history of prolonged use of any opioid, including products containing oxycodone, those with a history of drug or alcohol abuse, or those who use PERCOCET in combination with other abused drugs.

"Drug-seeking" behavior is very common in persons with substance use disorders. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing, or referral, repeated "loss" of prescriptions, tampering with prescriptions, and reluctance to provide prior medical records or contact information for other treating health care provider(s). "Doctor shopping" (visiting multiple prescribers to obtain additional prescriptions) is common among people who abuse drugs and people with substance use disorder. Preoccupation with achieving adequate pain relief can be appropriate behavior in a patient with inadequate pain control.

PERCOCET, like other opioids, can be diverted for nonmedical use into illicit channels of distribution. Careful record-keeping of prescribing information, including quantity, frequency, and renewal requests, as required by state and federal law, is strongly advised.

Proper assessment of the patient, proper prescribing practices, periodic reevaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.

Risks Specific to Abuse of PERCOCET

Abuse of PERCOCET poses a risk of overdose and death. The risk is increased with concurrent use of PERCOCET with alcohol and/or other CNS depressants.

Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death.

Parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and HIV.

Dependence

Both tolerance and physical dependence can develop during use of opioid therapy.

Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose).

Physical dependence is a state that develops as a result of a physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug.

Withdrawal may be precipitated through the administration of drugs with opioid antagonist activity (e.g., naloxone), mixed agonist/antagonist analgesics (e.g., pentazocine, butorphanol, nalbuphine), or partial agonists (e.g., buprenorphine). Physical dependence may not occur to a clinically significant degree until after several days to weeks of continued use.

Do not abruptly discontinue PERCOCET in a patient physically dependent on opioids. Rapid tapering of PERCOCET in a patient physically dependent on opioids may lead to serious withdrawal symptoms, uncontrolled pain, and suicide. Rapid discontinuation has also been associated with attempts to find other sources of opioid analgesics, which may be confused with drug-seeking for abuse.

When discontinuing PERCOCET, gradually taper the dosage using a patient-specific plan that considers the following: the dose of PERCOCET the patient has been taking, the duration of treatment, and the physical and psychological attributes of the patient. To improve the likelihood of a successful taper and minimize withdrawal symptoms, it is important that the opioid tapering schedule is agreed upon by the patient. In patients taking opioids for an extended period of time at high doses, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper [see DOSAGE AND ADMINISTRATION and WARNINGS].

Infants born to mothers physically dependent on opioids will also be physically dependent and may exhibit respiratory difficulties and withdrawal signs [see PRECAUTIONS; Pregnancy].

OVERDOSAGE

Following an acute overdosage, toxicity may result from the oxycodone or the acetaminophen.

Clinical Presentation

Acute overdosage with oxycodone can be manifested by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and, in some cases, pulmonary edema, bradycardia, hypotension, hypoglycemia, partial or complete airway obstruction, atypical snoring, and death. Marked mydriasis rather than miosis may be seen with hypoxia in overdose situations.

Acetaminophen

Dose-dependent potentially fatal hepatic necrosis is the most serious adverse effect of acetaminophen overdosage. Renal tubular necrosis, hypoglycemic coma, and coagulation defects may also occur.

Early symptoms following a potentially hepatotoxic overdose may include: nausea, vomiting, diaphoresis, and general malaise. Clinical and laboratory evidence of hepatic toxicity may not be apparent until 48 to 72 hours post-ingestion.

Treatment of Overdose

Oxycodone

In case of overdose, priorities are the reestablishment of a patent and protected airway and institution of assisted or controlled ventilation, if needed. Employ other supportive measures (including oxygen and vasopressors) in the management of circulatory shock and pulmonary edema as indicated. Cardiac arrest or arrhythmias will require advanced life-support measures.

Opioid antagonists, such as naloxone, are specific antidotes to respiratory depression resulting from opioid overdose. For clinically significant respiratory or circulatory depression secondary to opioid overdose, administer an opioid antagonist.

Because the duration of opioid reversal is expected to be less than the duration of action of oxycodone in PERCOCET, carefully monitor the patient until spontaneous respiration is reliably reestablished. If the response to an opioid antagonist is suboptimal or only brief in nature, administer additional antagonist as directed by the product's prescribing information.

In an individual physically dependent on opioids, administration of the recommended usual dosage of the antagonist will precipitate an acute withdrawal syndrome. The severity of the withdrawal symptoms experienced will depend on the degree of physical dependence and the dose of the antagonist administered. If a decision is made to treat serious respiratory depression in the physically dependent patient, administration of the antagonist should be initiated with care and by titration with smaller than usual doses of the antagonist.

Acetaminophen

Gastric decontamination with activated charcoal should be administered just prior to Nacetylcysteine (NAC) to decrease systemic absorption if acetaminophen ingestion is known or suspected to have occurred within a few hours of presentation. Serum acetaminophen levels should be obtained immediately if the patient presents 4 hours or more after ingestion to assess potential risk of hepatotoxicity; acetaminophen levels drawn less than 4 hours post-ingestion may be misleading. To obtain the best possible outcome, NAC should be administered as soon as possible where impending or evolving liver injury is suspected. Intravenous NAC may be administered when circumstances preclude oral administration.

Vigorous supportive therapy is required in severe intoxication. Procedures to limit the continuing absorption of the drug must be readily performed since the hepatic injury is dose dependent and occurs early in the course of intoxication.

DOSAGE AND ADMINISTRATION

Important Dosage and Administration Instructions

PERCOCET should be prescribed only by healthcare professionals who are knowledgeable about the use of opioids and how to mitigate the associated risks.

Use the lowest effective dosage for the shortest duration of time consistent with individual patient treatment goals [see WARNINGS]. Because the risk of overdose increases as opioid doses increase, reserve titration to higher doses of PERCOCET for

patients in whom lower doses are insufficiently effective and in whom the expected benefits of using a higher dose opioid clearly outweigh the substantial risks.

Many acute pain conditions (e.g., the pain that occurs with a number of surgical procedures or acute musculoskeletal injuries) require no more than a few days of an opioid analgesic. Clinical guidelines on opioid prescribing for some acute pain conditions are available.

There is variability in the opioid analgesic dose and duration needed to adequately manage pain due both to the cause of pain and to individual patient factors. Initiate the dosing regimen for each patient individually, taking into account the patient's underlying cause and severity of pain, prior analgesic treatment and response, and risk factors for addiction, abuse, and misuse [see WARNINGS].

Respiratory depression can occur at any time during opioid therapy, especially when initiating and following dosage increases with PERCOCET. Consider this risk when selecting an initial dose and when making dose adjustments [see WARNINGS].

Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose

Discuss the availability of naloxone for the emergency treatment of opioid overdose with the patient and caregiver and assess the potential need for access to naloxone, both when initiating and renewing treatment with PERCOCET [see WARNINGS; Life-Threatening Respiratory Depression, PRECAUTIONS; Information for Patients/Caregivers].

Inform patients and caregivers about the various ways to obtain naloxone as permitted by individual state naloxone dispensing and prescribing regulations (e.g., by prescription, directly from a pharmacist, or as part of a community-based program).

Consider prescribing naloxone, based on the patient's risk factors for overdose, such as concomitant use of CNS depressants, a history of opioid use disorder, or prior opioid overdose. The presence of risk factors for overdose should not prevent the proper management of pain in any given patient [see WARNINGS; Addiction, Abuse, and Misuse, Life-Threatening Respiratory Depression, Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants].

Consider prescribing naloxone when the patient has household members (including children) or other close contacts at risk for accidental ingestion or overdose.

Initial Dosage

Use of PERCOCET as the First Opioid Analgesic

Initiate treatment with PERCOCET using PERCOCET 2.5 mg/325 mg tablets in a dosing range of 1 to 2 tablets every 6 hours as needed for pain, at the lowest dose necessary to achieve adequate analgesia. Titrate the dose based upon the individual patient's response to their initial dose of PERCOCET. The total daily dose of acetaminophen should not exceed 4 grams.

The usual adult dosage is one tablet every 6 hours as needed for pain. The total daily dose of acetaminophen should not exceed 4 grams.

Strength	Usual Adult Dosage	Maximai Daily Dose
PERCOCET 2.5 mg/325 mg	1 or 2 tablets every 6 hours as needed for pain	12 Tablets
PERCOCET 5 mg/325 mg	1 tablet every 6 hours as needed for pain	12 Tablets
PERCOCET 7.5 mg/325 mg	1 tablet every 6 hours as needed for pain	8 Tablets
PERCOCET 10 mg/325 mg	1 tablet every 6 hours as needed for pain	6 Tablets

<u>Conversion from Oxycodone Hydrochloride and Acetaminophen to Extended-Release</u> <u>Oxycodone</u>

The relative bioavailability of Oxycodone Hydrochloride and Acetaminophen Tablets or Oral Solution compared to extended-release oxycodone is unknown, so conversion to extended-release oxycodone may lead to increased risk of excessive sedation and respiratory depression.

Titration and Maintenance of Therapy

Individually titrate PERCOCET to a dose that provides adequate analgesia and minimizes adverse reactions. Continually reevaluate patients receiving PERCOCET to assess the maintenance of pain control, signs and symptoms of opioid withdrawal, and other adverse reactions, as well as reassessing for the development of addiction, abuse, or misuse [see WARNINGS]. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration.

If the level of pain increases after dosage stabilization, attempt to identify the source of increased pain before increasing the PERCOCET dosage. If after increasing the dosage, unacceptable opioid-related adverse reactions are observed (including an increase in pain after dosage increase), consider reducing the dosage [see WARNINGS]. Adjust the dosage to obtain an appropriate balance between management of pain and opioid-related adverse reactions.

Safe Reduction or Discontinuation of Oxycodone Hydrochloride and Acetaminophen Tablets and Oral Solution

Do not abruptly discontinue PERCOCET in patients who may be physically dependent on opioids. Rapid discontinuation of opioid analgesics in patients who are physically dependent on opioids has resulted in serious withdrawal symptoms, uncontrolled pain, and suicide. Rapid discontinuation has also been associated with attempts to find other sources of opioid analgesics, which may be confused with drug-seeking for abuse. Patients may also attempt to treat their pain or withdrawal symptoms with illicit opioids, such as heroin, and other substances.

When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking PERCOCET, there are a variety of factors that should be considered, including the total daily dose of opioid (including PERCOCET) the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient. It is important to ensure ongoing care of the

patient and to agree on an appropriate tapering schedule and follow-up plan so that patient and provider goals and expectations are clear and realistic. When opioid analgesics are being discontinued due to a suspected substance use disorder, evaluate and treat the patient, or refer for evaluation and treatment of the substance use disorder. Treatment should include evidence-based approaches, such as medication assisted treatment of opioid use disorder. Complex patients with co-morbid pain and substance use disorders may benefit from referral to a specialist.

There are no standard opioid tapering schedules that are suitable for all patients. Good clinical practice dictates a patient-specific plan to taper the dose of the opioid gradually. For patients on PERCOCET who are physically opioid-dependent, initiate the taper by a small enough increment (e.g., no greater than 10% to 25% of the total daily dose) to avoid withdrawal symptoms, and proceed with dose-lowering at an interval of every 2 to 4 weeks. Patients who have been taking opioids for briefer periods of time may tolerate a more rapid taper.

It may be necessary to provide the patient with lower dosage strengths to accomplish a successful taper. Reassess the patient frequently to manage pain and withdrawal symptoms, should they emerge. Common withdrawal symptoms include restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis. Other signs and symptoms also may develop, including irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate. If withdrawal symptoms arise, it may be necessary to pause the taper for a period of time or raise the dose of the opioid analgesic to the previous dose, and then proceed with a slower taper. In addition, evaluate patients for any changes in mood, emergence of suicidal thoughts, or use of other substances.

When managing patients taking opioid analgesics, particularly those who have been treated for an extended period of time, and/or with high doses for chronic pain, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper. A multimodal approach to pain management may optimize the treatment of chronic pain, as well as assist with the successful tapering of the opioid analgesic [see WARNINGS; Withdrawal, DRUG ABUSE AND DEPENDENCE].

HOW SUPPLIED

PERCOCET (Oxycodone and Acetaminophen Tablets, USP) is supplied as follows:

2.5 mg/325 mg
Pink, oval, tablet, debossed with "PERCOCET" on one side and "2.5" on the other.
Bottles of 100 NDC 63481-627-70
5 mg/325 mg
Blue, round, tablet, debossed with "PERCOCET" and "5" on one side and bisect on the other.
Bottles of 100 NDC 63481-623-70
Bottles of 500 NDC 63481-623-85

7.5 mg/325 mg

Peach, oval-shaped, tablet, debossed with "PERCOCET" on one side and "7.5/325" on

the other. Bottles of 100

NDC 63481-628-70

10 mg/325 mg Yellow, capsule-shaped, tablet, debossed with "PERCOCET" on one side and "10/325" on the other. Bottles of 100 NDC 63481-629-70

Storage

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture. Dispense in a tight, light-resistant container as defined in the USP.

Store PERCOCET securely and dispose of properly [see PRECAUTIONS; Information for Patients/Caregivers].

Manufactured for: Endo USA Malvern, PA 19355

© 2024 Endo, Inc. or one of its affiliates.

Revised: June 2024

Medication Guide PERCOCET[®] ('pər-kō-,set) (oxycodone and acetaminophen) Tablets, CII

PERCOCET is:

- A strong prescription pain medicine that contains an opioid (narcotic) that is used to manage pain, severe enough to require an opioid analgesic and for which alternative treatments are inadequate and when other pain treatments such as non-opioid pain medicines do not treat your pain well enough or you cannot tolerate them.
- An opioid pain medicine that can put you at risk for overdose and death. Even if you take your dose correctly as prescribed you are at risk for opioid addiction, abuse, and misuse that can lead to death.

Important information about PERCOCET tablets:

- Get emergency help or call 911 right away if you take too much PERCOCET (overdose). When you first start taking PERCOCET, when your dose is changed, or if you take too much (overdose), serious or life-threatening breathing problems that can lead to death may occur. Talk to your healthcare provider about naloxone, a medicine for the emergency treatment of an opioid overdose. Taking PERCOCET with other opioid medicines, benzodiazepines, alcohol, or other central nervous system depressants (including street drugs) can cause severe drowsiness, decreased awareness, breathing problems, coma, and death.
- Never give anyone else your PERCOCET. They could die from taking it. Selling or giving away PERCOCET is against the law.
- Store PERCOCET securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home.

Do not take PERCOCET if you have:

- Severe asthma, trouble breathing, or other lung problems.
- A bowel blockage or have narrowing of the stomach or intestines.
- Known hypersensitivity to oxycodone, acetaminophen, or any ingredient in PERCOCET

Before taking PERCOCET, tell your healthcare provider if you have a history of:

- Head injury, seizures
- Liver, kidney, thyroid problems
- Problems urinating
- Pancreas or gallbladder problems
- Abuse of street or prescription drugs, alcohol addiction, opioid overdose, or mental health problem

Tell your healthcare provider if you are:

- Noticing your pain getting worse. If your pain gets worse after you take PERCOCET, do not take more of PERCOCET without first talking to your healthcare provider. Talk to your healthcare provider if the pain that you have increases, if you feel more sensitive to pain, or if you have new pain after taking PERCOCET.
- **Pregnant or planning to become pregnant.** Use of PERCOCET for an extended period of time during pregnancy can cause withdrawal symptoms in your newborn baby that could be life-threatening if not recognized and treated.
- **Breastfeeding.** PERCOCET passes into breast milk and may harm your baby. Carefully observe infants for increased sleepiness (more than usual), breathing difficulties, or limpness. Seek immediate medical care if you notice these signs.
- Living in a household where there are small children or someone who has abused street or prescription drugs.
- Taking prescription or over-the-counter medicines, vitamins, or herbal supplements. Taking PERCOCET with certain other medicines can cause serious side effects that could lead to death.

When taking PERCOCET:

- Do not change your dose. Take PERCOCET exactly as prescribed by your healthcare provider. Use the lowest dose possible for the shortest time needed.
- For acute (short-term) pain, you may only need to take PERCOCET for a few days. You may have some PERCOCET left over that you did not use. See disposal information at the bottom of this section for directions on how to safely throw away (dispose of) your unused PERCOCET.
- Take your prescribed dose every 6 hours at the same time every day as needed for pain. Do not take more than your prescribed dose. If you miss a dose, take your next dose at your usual time.
- Call your healthcare provider if the dose you are taking does not control your pain.
- If you have been taking PERCOCET regularly, do not stop taking PERCOCET without talking to your healthcare provider.

• Dispose of expired, unwanted, or unused PERCOCET by promptly flushing down the toilet, if a drug take-back option is not readily available. Visit www.fda.gov/drugdisposal for additional information on disposal of unused medicines.

While taking PERCOCET DO NOT:

- Drive or operate heavy machinery, until you know how PERCOCET affects you. PERCOCET can make you sleepy, dizzy, or lightheaded.
- Drink alcohol or use prescription or over-the-counter medicines that contain alcohol. Using products containing alcohol during treatment with PERCOCET may cause you to overdose and die.

The possible side effects of PERCOCET:

• Constipation, nausea, sleepiness, vomiting, tiredness, headache, dizziness, abdominal pain. Call your healthcare provider if you have any of these symptoms and they are severe.

Get emergency medical help or call 911 right away if you have:

• Trouble breathing, shortness of breath, fast heartbeat, chest pain, swelling of your face, tongue, or throat, extreme drowsiness, light-headedness when changing positions, feeling faint, agitation, high body temperature, trouble walking, stiff muscles, or mental changes such as confusion.

These are not all the possible side effects of PERCOCET. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. For more information go to dailymed.nlm.nih.gov, www.endo.com or call 1-800-828-9393.

Manufactured for: Endo USA Malvern, PA 19355 1-800-462-3636 © 2024 Endo, Inc. or one of its affiliates.

This Medication Guide has been approved by the U.S. Food and Drug Administration.

R06/2024

Package Label - Principal Display Panel - 2.5 mg/325 mg 100 Count Bottle



Package Label - Principal Display Panel - 5 mg/325 mg 100 Count Bottle



Package Label - Principal Display Panel - 7.5 mg/325 mg 100 Count Bottle



Package Label - Principal Display Panel - 10 mg/325 mg 100 Count Bottle



PERCOCET						
oxycodone hydrochlorid	e and a	acetaminophen tablet				
Product Information	-					
Product Information	n					
Product Type	ŀ	HUMAN PRESCRIPTION DRUG	Item Code	e (Source)	NDC	2:63481-627
oute of Administration ORAL DEA Schedule CII						
Active Ingredient/Ac	tive M	loiety				
	Ingred	ient Name		Basis of Strei	ngth	Strength
OXYCODONE HYDROCHLO UNII:CD35PMG570)	RIDE (U	INII: C1ENJ2TE6C) (OXYCODOI	NE -	OXYCODONE HYDROCHLORIDE		2.5 mg
ACETAMINOPHEN (UNII: 36	209ITL9	D) (ACETAMINOPHEN - UNII:36	5209ITL9D)	ACETAMINOPHEN		325 mg
Inactive Ingredients						
mactive myrealents	•	Ingredient Name			St	rength
SILICON DIOXIDE (UNII: ET)	7Z6XBU	-				· · · · · · · ·
CROSCARMELLOSE SODIU						
CROSPOVIDONE (UNII: 257	830E561	1)				
CELLULOSE, MICROCRYST	ALLINE	(UNII: OP1R32D61U)				
POVIDONE (UNII: FZ989GH9	94E)					
STARCH, CORN (UNII: 0823	-					
STEARIC ACID (UNII: 4ELV72						
FD&C RED NO. 40 (UNII: W.	ZB9127>	(OA)				
Product Characteris	tics					
Color	pink	Score		no score		
Shape	OVAL	Size		17mm		
Flavor		Imprint Code		PERCOCET;2;5		

	ckaging						
#	Item Code	Pao	ckage Description		eting Start Date		eting End Date
	NDC:63481-627- 70	100 in 1 BOTT Product	LE; Type 0: Not a Combination	06/30/19	99		
M	arketing I	nformat	ion				
	Marketing Category		tion Number or Monogra Citation	ph Mar	keting Start Date	Marl	keting End Date
ANE	AC	ANDA04033	0	06/30/	1999		
_		ala la vial a la va d					
Эху		chionde and	l acetaminophen tablet				
Pr	oduct Inform	mation					
Pro	oduct Type		HUMAN PRESCRIPTION DRUG	Item Code	e (Source)	N	DC:63481-623
Ro	ute of Adminis	stration	ORAL	DEA Sche	dule	С	II
Ac	tive Ingredie	ent/Active	Moiety				
		Ingre	dient Name		Basis of S	trength	Strengt
ox		Ingre		NE -	Basis of S OXYCODONE HYDROCHLORIE	-	Strengt 5 mg
OX UNI	YCODONE HYDF I:CD35PMG570)	Ingre ROCHLORIDE	dient Name		OXYCODONE	DE	
OX UNI	YCODONE HYDF I:CD35PMG570)	Ingre ROCHLORIDE	dient Name (UNII: C1ENJ2TE6C) (OXYCODO		OXYCODONE HYDROCHLORIE	DE	5 mg
OX UNI ACI	YCODONE HYDF I:CD35PMG570)	Ingre ROCHLORIDE (UNII: 36209ITL	dient Name (UNII: C1ENJ2TE6C) (OXYCODO		OXYCODONE HYDROCHLORIE	DE	5 mg
OX UNI ACI	YCODONE HYDF I:CD35PMG570) ETAMINOPHEN (Ingre ROCHLORIDE (UNII: 36209ITL	dient Name (UNII: C1ENJ2TE6C) (OXYCODO		OXYCODONE HYDROCHLORIE	DE EN	5 mg
ox UNI ACI	YCODONE HYDF I:CD35PMG570) ETAMINOPHEN (Ingre ROCHLORIDE (UNII: 36209ITL dients	dient Name (UNII: C1ENJ2TE6C) (OXYCODO .9D) (ACETAMINOPHEN - UNII:34 Ingredient Name		OXYCODONE HYDROCHLORIE	DE EN	5 mg 325 mg
OX UNI ACI SIL	YCODONE HYDF I:CD35PMG570) ETAMINOPHEN (Active Ingree ICON DIOXIDE (OSCARMELLOSE	Ingre ROCHLORIDE (UNII: 36209ITL dients UNII: ETJ7Z6XB SODIUM (UN	edient Name (UNII: C1ENJ2TE6C) (OXYCODO -9D) (ACETAMINOPHEN - UNII:30 Ingredient Name 804) II: M28OL1HH48)		OXYCODONE HYDROCHLORIE	DE EN	5 mg 325 mg
OX UNI ACI SIL CR CR	YCODONE HYDF I:CD35PMG570) ETAMINOPHEN (Active Ingree ICON DIOXIDE (U OSCARMELLOSE OSPOVIDONE (U	Ingre ROCHLORIDE (UNII: 36209ITL dients UNII: ETJ7Z6XB SODIUM (UN	edient Name (UNII: C1ENJ2TE6C) (OXYCODO L9D) (ACETAMINOPHEN - UNII: 34 Ingredient Name 804) II: M28OL1HH48) 61)		OXYCODONE HYDROCHLORIE	DE EN	5 mg 325 mg
OX UNI ACI SIL CR CR CR	YCODONE HYDF I:CD35PMG570) ETAMINOPHEN (Active Ingred ICON DIOXIDE (OSCARMELLOSE OSPOVIDONE (U LLULOSE, MICRO	Ingre ROCHLORIDE (UNII: 36209ITL dients UNII: ETJ7Z6XB SODIUM (UN JNII: 257830E50 OCRYSTALLIN	edient Name (UNII: C1ENJ2TE6C) (OXYCODO -9D) (ACETAMINOPHEN - UNII:30 Ingredient Name 804) II: M28OL1HH48)		OXYCODONE HYDROCHLORIE	DE EN	5 mg 325 mg
OX UNI ACI SIL CR CR CR CR	YCODONE HYDF I:CD35PMG570) ETAMINOPHEN (Active Ingree ICON DIOXIDE (OSCARMELLOSE OSPOVIDONE (U LLULOSE, MICRO VIDONE (UNII: FZ	Ingre ROCHLORIDE (UNII: 36209ITL dients UNII: ETJ7Z6XB SODIUM (UN UNII: 2S7830E50 OCRYSTALLIN 2989GH94E)	edient Name (UNII: C1ENJ2TE6C) (OXYCODO L9D) (ACETAMINOPHEN - UNII:34 Ingredient Name 804) II: M28OL1HH48) 61) IE (UNII: OP1R32D61U)		OXYCODONE HYDROCHLORIE	DE EN	5 mg 325 mg
OX UNI ACI SIL CR CR CR CR CR CR CR ST/	YCODONE HYDF I:CD35PMG570) ETAMINOPHEN (ACTIVE INGREE ICON DIOXIDE (OSCARMELLOSE OSPOVIDONE (U LLULOSE, MICRE VIDONE (UNII: FZ ARCH, CORN (UN	Ingre ROCHLORIDE (UNII: 36209ITL dients UNII: ETJ7Z6XB SODIUM (UN UNII: 257830E50 OCRYSTALLIN 2989GH94E) UII: 08232NY35	edient Name (UNII: C1ENJ2TE6C) (OXYCODO 9D) (ACETAMINOPHEN - UNII:30 Ingredient Name 804) II: M28OL1HH48) 61) IE (UNII: OP1R32D61U)		OXYCODONE HYDROCHLORIE	DE EN	5 mg 325 mg
OX UNI ACI SIL CR CR CR CR CR CR STI STI	YCODONE HYDF I:CD35PMG570) ETAMINOPHEN (ACTIVE INGRE ICON DIOXIDE (OSCARMELLOSE OSPOVIDONE (U LLULOSE, MICRO VIDONE (UNII: FZ ARCH, CORN (UNI EARIC ACID (UNII	Ingre ROCHLORIDE (UNII: 36209ITL (UNII: 36209ITL dients UNII: ETJ7Z6XB SODIUM (UN INII: 257830E50 OCRYSTALLIN 2989GH94E) III: 08232NY3S I: 4ELV7Z65AP)	dient Name (UNII: C1ENJ2TE6C) (OXYCODO 9D) (ACETAMINOPHEN - UNII:30 Ingredient Name 8U4) II: M28OL1HH48) 61) IE (UNII: OP1R32D61U) J)		OXYCODONE HYDROCHLORIE	DE EN	5 mg 325 mg
OX UNI ACI SIL CRI CRI CRI CRI SIL SIL	YCODONE HYDF I:CD35PMG570) ETAMINOPHEN (ACTIVE INGREE ICON DIOXIDE (OSCARMELLOSE OSPOVIDONE (U LLULOSE, MICRE VIDONE (UNII: FZ ARCH, CORN (UN	Ingre ROCHLORIDE (UNII: 36209ITL (UNII: 36209ITL dients UNII: ETJ7Z6XB SODIUM (UN INII: 257830E50 OCRYSTALLIN 2989GH94E) III: 08232NY3S I: 4ELV7Z65AP)	dient Name (UNII: C1ENJ2TE6C) (OXYCODO 9D) (ACETAMINOPHEN - UNII:30 Ingredient Name 8U4) II: M28OL1HH48) 61) IE (UNII: OP1R32D61U) J)		OXYCODONE HYDROCHLORIE	DE EN	5 mg 325 mg
OX UNI ACI SIL CR(CR) CR(CR) CR(CR) CR(STI FD)	YCODONE HYDF I:CD35PMG570) ETAMINOPHEN (ACTIVE INGRE ICON DIOXIDE (OSCARMELLOSE OSPOVIDONE (U LLULOSE, MICRO VIDONE (UNII: FZ ARCH, CORN (UNI EARIC ACID (UNII	Ingre ROCHLORIDE (UNII: 36209ITL dients UNII: ETJ7Z6XB SODIUM (UN UNII: 257830E5) OCRYSTALLIN 2989GH94E) UII: 08232NY3S I: 4ELV7Z65AP) (UNII: H3R47K3	dient Name (UNII: C1ENJ2TE6C) (OXYCODO 9D) (ACETAMINOPHEN - UNII:30 Ingredient Name 8U4) II: M28OL1HH48) 61) IE (UNII: OP1R32D61U) J)		OXYCODONE HYDROCHLORIE	DE EN	5 mg 325 mg
OX UNI ACI SIL CR CR CR CR CR CR CR CR STI FD STI FD	YCODONE HYDF I:CD35PMG570) ETAMINOPHEN (ACTIVE INGREE ICON DIOXIDE (OSCARMELLOSE OSPOVIDONE (U LLULOSE, MICRE VIDONE (UNII: FZ ARCH, CORN (UNII: EARIC ACID (UNII: &C BLUE NO. 1	Ingre ROCHLORIDE (UNII: 36209ITL dients UNII: ETJ7Z6XB SODIUM (UN UNII: 257830E5) OCRYSTALLIN 2989GH94E) UII: 08232NY3S I: 4ELV7Z65AP) (UNII: H3R47K3	dient Name (UNII: C1ENJ2TE6C) (OXYCODO 9D) (ACETAMINOPHEN - UNII:30 Ingredient Name 8U4) II: M28OL1HH48) 61) IE (UNII: OP1R32D61U) J)		OXYCODONE HYDROCHLORIE	DE EN SN SN SN SN SN SN SN SN SN SN SN SN SN	5 mg 325 mg
OX UNI ACI SIL CR CR CR CR CR CR CR CR CR CR CR CR CR	YCODONE HYDF I:CD35PMG570) ETAMINOPHEN (ACTIVE INGREE ICON DIOXIDE (OSCARMELLOSE OSPOVIDONE (U LLULOSE, MICRO VIDONE (UNII: FZ ARCH, CORN (UNII: EARIC ACID (UNII &C BLUE NO. 1 Oduct Chara Ior	Ingre ROCHLORIDE (UNII: 36209ITL dients UNII: ETJ7Z6XB SODIUM (UN INII: 257830E50 OCRYSTALLIN 2989GH94E) III: 08232NY35 I: 4ELV7Z65AP) (UNII: H3R47K3	edient Name (UNII: C1ENJ2TE6C) (OXYCODO .9D) (ACETAMINOPHEN - UNII: 34 Ingredient Name 804) II: M280L1HH48) 61) IE (UNII: OP1R32D61U) J) 3TBD) Score		OXYCODONE HYDROCHLORIE ACETAMINOPHE	DE EN SN SN SN SN SN SN SN SN SN SN SN SN SN	5 mg 325 mg
OX UNI ACI SIL CR CR CR CR CR CR CR CR CR T STI STI FD STI	YCODONE HYDF I:CD35PMG570) ETAMINOPHEN (ACTIVE INGREE ICON DIOXIDE (OSCARMELLOSE OSPOVIDONE (U LLULOSE, MICRE VIDONE (UNII: FZ ARCH, CORN (UNII: EARIC ACID (UNII: &C BLUE NO. 1	Ingre ROCHLORIDE (UNII: 36209ITL dients UNII: ETJ7Z6XB SODIUM (UN UNII: 257830E50 OCRYSTALLIN 2989GH94E) UII: 08232NY35 I: 4ELV7Z65AP) (UNII: H3R47K3 OCCEPTISTICS blue	edient Name (UNII: C1ENJ2TE6C) (OXYCODO .9D) (ACETAMINOPHEN - UNII:30 .9D) (ACETAMINOPHEN - UNII:30		OXYCODONE HYDROCHLORIE ACETAMINOPHE 2 piece	DE EN SN SS SS	5 mg 325 mg
OX UNI ACI SIL CR(CR(CR(CR(CR(CR(CR(CR(CR(CR(ACTIVE INGRESSION ACTIVE INGRESSION ACTIVE INGRESSION ACTIVE INGRESSION ACTIVE INGRESSION ACTIVE INGRESSION ACTIVE (UNIL ACCH, CORN	Ingre ROCHLORIDE (UNII: 36209ITL dients UNII: ETJ7Z6XB SODIUM (UN UNII: 257830E50 OCRYSTALLIN 2989GH94E) UII: 08232NY35 I: 4ELV7Z65AP) (UNII: H3R47K3 OCCEPTISTICS blue	edient Name (UNII: C1ENJ2TE6C) (OXYCODO .9D) (ACETAMINOPHEN - UNII: 34 Ingredient Name 804) II: M280L1HH48) 61) IE (UNII: OP1R32D61U) J) 3TBD) Score		OXYCODONE HYDROCHLORIE ACETAMINOPHE 2 piece 11mm	DE EN SN SS SS	5 mg 325 mg

	ackaging						
#	Item Code	Pac	kage Description		eting Start Date		ting End Date
1	NDC:63481-623- 70	100 in 1 BOTT Product	LE; Type 0: Not a Combination	06/30/199	99		
2	NDC:63481-623- 85	500 in 1 BOTT Product	LE; Type 0: Not a Combination	06/30/199	99	03/31/202	5
M	arketing			_			
	Marketing Category	Applicat	tion Number or Monogra _l Citation	oh Mar	keting Start Date		eting End Date
AN	DA	ANDA04033)	06/30/	1999		
	DCOCET						
	ERCOCET vcodone hvdro	chloride and	acetaminophen tablet				
-	· · · ·						
P	roduct Infor	mation					
Pr	oduct Type		HUMAN PRESCRIPTION DRUG	Item Code	(Source)	ND	C:63481-628
Ro	oute of Admini	stration	ORAL	DEA Schee	dule	CII	
A	tive Ingredi	ent/Active	Moiety				
	-	Ingre	dient Name		Basis of S	trength	Strengt
0>	-	Ingre		IE -	Basis of S OXYCODONE HYDROCHLORIE	-	Strengt 7.5 mg
O) UN	(YCODONE HYDI III:CD35PMG570)	Ingre ROCHLORIDE	dient Name		OXYCODONE	DE	
O) UN	(YCODONE HYDI III:CD35PMG570)	Ingre ROCHLORIDE	dient Name (UNII: C1ENJ2TE6C) (OXYCODON		OXYCODONE HYDROCHLORIE	DE	7.5 mg
0) UN AC	(YCODONE HYDI III:CD35PMG570)	Ingre ROCHLORIDE (UNII: 36209ITL	dient Name (UNII: C1ENJ2TE6C) (OXYCODON		OXYCODONE HYDROCHLORIE	DE	7.5 mg
o) UN AC	CYCODONE HYDI	Ingre ROCHLORIDE (UNII: 36209ITL dients	dient Name (UNII: C1ENJ2TE6C) (OXYCODON 9D) (ACETAMINOPHEN - UNII:36 Ingredient Name		OXYCODONE HYDROCHLORIE	DE :N	7.5 mg
o) UN AC	AYCODONE HYDI III:CD35PMG570) ETAMINOPHEN ACTIVE Ingre	Ingre ROCHLORIDE (UNII: 36209ITL dients (UNII: ETJ7Z6XB	dient Name (UNII: C1ENJ2TE6C) (OXYCODON 9D) (ACETAMINOPHEN - UNII:36 Ingredient Name U4)		OXYCODONE HYDROCHLORIE	DE :N	7.5 mg 325 mg
OX UN AC	CYCODONE HYDI III:CD35PMG570) ETAMINOPHEN ACTIVE INGRE	Ingre ROCHLORIDE (UNII: 36209ITL dients (UNII: ETJ7Z6XB E SODIUM (UN	dient Name (UNII: C1ENJ2TE6C) (OXYCODON 9D) (ACETAMINOPHEN - UNII:36 Ingredient Name U4) II: M28OL1HH48)		OXYCODONE HYDROCHLORIE	DE :N	7.5 mg 325 mg
OX UN AC In SII CR	AYCODONE HYDI III:CD35PMG570) EETAMINOPHEN ACTIVE INGRE LICON DIOXIDE (L COSCARMELLOSI	Ingre ROCHLORIDE (UNII: 36209ITL dients (UNII: ETJ7Z6XB E SODIUM (UN JNII: 257830E5(dient Name (UNII: C1ENJ2TE6C) (OXYCODON 9D) (ACETAMINOPHEN - UNII:36 Ingredient Name U4) II: M28OL1HH48) 51)		OXYCODONE HYDROCHLORIE	DE :N	7.5 mg 325 mg
O) UN AC In SII CR CR	AYCODONE HYDI III:CD35PMG570) EETAMINOPHEN ACTIVE INGRE LICON DIOXIDE (L COSCARMELLOSI	Ingre ROCHLORIDE (UNII: 36209ITL dients (UNII: ETJ7Z6XB E SODIUM (UN JNII: 257830E56 OCRYSTALLIN	dient Name (UNII: C1ENJ2TE6C) (OXYCODON 9D) (ACETAMINOPHEN - UNII:36 Ingredient Name U4) II: M28OL1HH48)		OXYCODONE HYDROCHLORIE	DE :N	7.5 mg 325 mg
O) UN AC In SII CR CR CR CP	ACCODONE HYDI III:CD35PMG570) ETAMINOPHEN ACTIVE Ingre ACTIVE Ingre COSCARMELLOSI ACOSPOVIDONE (L COSPOVIDONE (L COSE, MICR	Ingre ROCHLORIDE (UNII: 36209ITL dients (UNII: ETJ7Z6XB E SODIUM (UN JNII: 257830E56 OCRYSTALLIN Z989GH94E)	dient Name (UNII: C1ENJ2TE6C) (OXYCODON 9D) (ACETAMINOPHEN - UNII:36 Ingredient Name U4) II: M28OL1HH48) 51) E (UNII: OP1R32D61U)		OXYCODONE HYDROCHLORIE	DE :N	7.5 mg 325 mg
OX UN AC In SII CR CR CR CR CR ST	CYCODONE HYDI III:CD35PMG570) ETAMINOPHEN ACTIVE INGRE LICON DIOXIDE (COSCARMELLOSI COSPOVIDONE (UNII: F2	Ingre ROCHLORIDE (UNII: 36209ITL dients (UNII: ETJ7Z6XB E SODIUM (UN JNII: 257830E56 OCRYSTALLIN 2989GH94E) NII: 08232NY35	dient Name (UNII: C1ENJ2TE6C) (OXYCODON 9D) (ACETAMINOPHEN - UNII:36 Ingredient Name U4) II: M28OL1HH48) 51) E (UNII: OP1R32D61U) I)		OXYCODONE HYDROCHLORIE	DE :N	7.5 mg 325 mg
OX UN AC In SII CR CR CR CR ST ST	ACCODONE HYDI III:CD35PMG570) ETAMINOPHEN ACTIVE Ingre ACTIVE Ingre ACTIVE Ingre ACTIVE Ingre ACTIVE INGR ACCONDIOXIDE (UNII: F2 ARCH, CORN (UNII: F2 ARCH, CORN (UNII: F2	Ingre ROCHLORIDE (UNII: 36209ITL dients (UNII: ETJ7Z6XB E SODIUM (UN JNII: 257830E56 OCRYSTALLIN Z989GH94E) NII: 08232NY35 II: 4ELV7Z65AP)	dient Name (UNII: C1ENJ2TE6C) (OXYCODON 9D) (ACETAMINOPHEN - UNII:36 Ingredient Name U4) II: M28OL1HH48) 51) E (UNII: OP1R32D61U) I)		OXYCODONE HYDROCHLORIE	DE :N	7.5 mg 325 mg
OX UN AC In SII CR CR CR CR ST ST	CYCODONE HYDI III:CD35PMG570) ETAMINOPHEN ACTIVE INGRE ACTIVE INGRE ACTIVE INGRE ACTIVE INGRE ACTIVE INGRE ACTIVE ACID (UNI EARIC ACID (UNI	Ingre ROCHLORIDE (UNII: 36209ITL dients (UNII: ETJ7Z6XB E SODIUM (UN JNII: 257830E56 OCRYSTALLIN Z989GH94E) NII: 08232NY35 II: 4ELV7Z65AP)	dient Name (UNII: C1ENJ2TE6C) (OXYCODON 9D) (ACETAMINOPHEN - UNII:36 Ingredient Name U4) II: M28OL1HH48) 51) E (UNII: OP1R32D61U) I)		OXYCODONE HYDROCHLORIE	DE :N	7.5 mg 325 mg
OX UN AC In SII CR CR CR CR ST ST FD	CYCODONE HYDI III:CD35PMG570) ETAMINOPHEN ACTIVE INGRE ACTIVE INGRE ACTIVE INGRE ACTIVE INGRE ACTIVE INGRE ACTIVE ACID (UNI EARIC ACID (UNI	Ingre ROCHLORIDE (UNII: 36209ITL dients (UNII: ETJ7Z6XB E SODIUM (UN JNII: 257830E56 OCRYSTALLIN 2989GH94E) NII: 08232NY3S II: 4ELV7Z65AP) 0. 6 (UNII: H77V	dient Name (UNII: C1ENJ2TE6C) (OXYCODON 9D) (ACETAMINOPHEN - UNII:36 Ingredient Name U4) II: M28OL1HH48) 51) E (UNII: OP1R32D61U) I)		OXYCODONE HYDROCHLORIE	DE :N	7.5 mg 325 mg
OX UN AC IN SII CR CR CR CR ST ST FD	ACC YELLOW NO	Ingre ROCHLORIDE (UNII: 36209ITL dients (UNII: ETJ7Z6XB E SODIUM (UN JNII: 257830E56 OCRYSTALLIN 2989GH94E) NII: 08232NY3S II: 4ELV7Z65AP) 0. 6 (UNII: H77V	dient Name (UNII: C1ENJ2TE6C) (OXYCODON 9D) (ACETAMINOPHEN - UNII:36 Ingredient Name U4) II: M28OL1HH48) 51) E (UNII: OP1R32D61U) I)	209ITL9D)	OXYCODONE HYDROCHLORIE	DE :N	7.5 mg 325 mg
O) UN AC In SII CR CE PC ST ST FD PI Cc	CYCODONE HYDI III:CD35PMG570) ETAMINOPHEN ACTIVE INGRE ACTIVE INGRE	Ingre ROCHLORIDE (UNII: 36209ITL dients (UNII: ETJ7Z6XB E SODIUM (UN JNII: 257830E56 OCRYSTALLIN Z989GH94E) NII: 08232NY35 II: 4ELV7Z65AP) O. 6 (UNII: H77V	dient Name (UNII: C1ENJ2TE6C) (OXYCODON 9D) (ACETAMINOPHEN - UNII:36 Ingredient Name U4) II: M28OL1HH48) 51) E (UNII: OP1R32D61U) I) EI93A8)	2O9ITL9D)	OXYCODONE HYDROCHLORIE ACETAMINOPHE	DE :N	7.5 mg 325 mg
OX UN AC SII CR CR CR CR ST FD FD CC ST FD	ACC YELLOW NO	Ingre ROCHLORIDE ((UNII: 36209ITL dients (UNII: ETJ7Z6XB E SODIUM (UN JNII: 257830E5(OCRYSTALLIN Z989GH94E) NII: 08232NY35 II: 4ELV7Z65AP) O. 6 (UNII: H77V Acteristics orange	dient Name (UNII: C1ENJ2TE6C) (OXYCODON 9D) (ACETAMINOPHEN - UNII: 36 Ingredient Name U4) 11: M28OL1HH48) 51) E (UNII: OP1R32D61U) [) EI93A8) Score	2O9ITL9D)	OXYCODONE HYDROCHLORIE ACETAMINOPHE	DE IN IN IN IN IN IN IN IN IN IN IN IN IN	7.5 mg 325 mg

Packaging						
# Item Code	Package Description	Marketing Start Date	Marketing End Date			
1 NDC:63481-628-70	100 in 1 BOTTLE; Type 0: Not a Combination Product	11/30/2001				
Marketing	Information					
-	Information Application Number or Monograph	Marketing Start	Marketing End			
Marketing Marketing Category	Information Application Number or Monograph Citation	Marketing Start Date	Marketing End Date			

PERCOCET							
oxycodone hydrochl	oride and	acetam	inophen tablet				
Product Informa	tion						
Product Type		HUMAN P	RESCRIPTION DRUG	Item Code	e (Source)	NDC	:63481-629
Route of Administra	ation	ORAL		DEA Schee	dule	CII	
Active Ingredient	Active	Moiety					
	Ingre	dient Na	ame		Basis of Streng	gth	Strength
OXYCODONE HYDROC UNII:CD35PMG570)	HLORIDE	(UNII: C1E	NJ2TE6C) (OXYCODOI	NE -	OXYCODONE HYDROCHLORIDE		10 mg
ACETAMINOPHEN (UNI	I: 36209ITL	.9D) (ACET	AMINOPHEN - UNII:36	209ITL9D)	ACETAMINOPHEN		325 mg
Inactive Ingredie	nts						
		-	dient Name			Str	ength
SILICON DIOXIDE (UNII	-						
CROSCARMELLOSE SC CROSPOVIDONE (UNII:			.HH48)				
CELLULOSE, MICROCE			P1B32D61U)				
POVIDONE (UNII: FZ989			1110200107				
STARCH, CORN (UNII: C		J)					
STEARIC ACID (UNII: 4E	ELV7Z65AP))					
D&C YELLOW NO. 10	(UNII: 35SV	V5USQ3G)					
Product Characte	eristics						
Color	yellow		Score		no score		
Shape	CAPSULE		Size		15mm		
Flavor			Imprint Code		PERCOCET;10;325		
Contains							

Item Code	Package Description	Marketing Start	Marketing End				
IDC:63481-629-		Package Description Marketing Start Marketi Date Da					
	100 in 1 BOTTLE; Type 0: Not a Combination Product	11/30/2001					
arketing I	nformation						
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date				
A	ANDA040330	11/30/2001					
	Marketing Category	Category Citation	Marketing CategoryApplication Number or Monograph CitationMarketing Start Date				

Labeler - Endo USA, Inc. (119185057)

Revised: 10/2024

Endo USA, Inc.